{"id":"W2603191492","doi":"10.1200/jco.2012.30.15_suppl.1025","title":"NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital du Saint-Sacrement; Montreal General Hospital; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Pazopanib; Medicine; Internal medicine; Breast cancer; Clinical endpoint; Regimen; Oncology; Phases of clinical research; Chemotherapy; Tyrosine-kinase inhibitor; Cancer; Urology; Gastroenterology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001280595,0.001209027,0.00123119,0.000444994,0.0003154471,0.0006540359,0.0008026689,0.001064318,0.005016842],"category_scores_gemma":[0.0006798419,0.0004841898,0.0006737448,0.0003495747,0.0009004257,0.0006398845,0.0004181281,0.003001265,0.001163271],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008383596,"about_ca_system_score_gemma":0.001276425,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009805644,"about_ca_topic_score_gemma":0.003284137,"domain_scores_codex":[0.9997815,0.00009764668,0.0000112933,0.00003300213,0.00003095141,0.00004554906],"domain_scores_gemma":[0.9996843,0.00004323852,0.00006117179,0.00001563475,0.00001325443,0.0001824787],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7594469,0.04030121,0.005752515,0.001539378,0.001017626,0.0005107802,0.0002545987,0.003918203,0.03982241,0.000530861,0.007561686,0.1393438],"study_design_scores_gemma":[0.7547871,0.2230482,0.008924398,0.00008168793,0.0003446859,0.0007398091,0.00004225041,0.002221638,0.004292313,0.0002004807,0.005286373,0.0000310271],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894646,0.002639426,0.0004146381,0.0005664363,0.0001677198,0.002469167,0.001243733,0.0001334705,0.00290068],"genre_scores_gemma":[0.9791531,0.003193484,0.002547218,0.0009610274,0.0001856099,0.003035853,0.004810424,0.0000277986,0.006085651],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005016842,"threshold_uncertainty_score":0.016783,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08320078400952502,"score_gpt":0.5089545598580594,"score_spread":0.4257537758485344,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}